Call for Science Is Open

Submit your abstracts of original research for the opportunity to present to thousands of your colleagues worldwide. Research can be in the form of clinical studies, basic science investigations, or preclinical studies and must be relevant to interventional cardiology, endovascular medicine, or structural heart disease. Your abstracts must convey original research but can include portions of previous abstracts and/or manuscripts presented or published elsewhere. Abstracts that are selected will be published in the Journal of the American College of Cardiology (JACC).

Note: Submit single-patient case reports to Challenging Cases, regardless of the novelty of the case.

Guidelines: Character limit is 2,200, including spaces (approximately 300-350 words).

Notification: Accepted presenters will be notified in mid-August.

Physicians and fellows from around the world, submit your most challenging coronary, endovascular, and structural heart disease cases. The best cases will be chosen by the course directors for presentation.

Guidelines: Character limit is 2,450 total for case summary, history, diagnostic tests, procedure, conclusion, comments. PowerPoint slide presentation highlighting your case is optional. Images: 10 MB. Video formats accepted: 30 MB mpeg, wmv, avi, mov, mpg, mp4.

Notification: Accepted presenters will be notified in mid-August.

TCT Innovation Sessions

Submit your novel technologies relevant to the monitoring, diagnosis, and treatment of coronary, endovascular, or structural heart disease. Selected emerging technologies will be presented at TCT 2023.

TCT Shark Tank Innovation Competition

Enter the Shark Tank! The annual TCT meeting is the preeminent platform for concept-stage presentations of novel technologies in interventional cardiovascular medicine. Submit concept-stage novel technologies in interventional cardiovascular medicine for a chance to present to a panel of expert judges.

Your submission must be relevant to the monitoring, diagnosis, or treatment of coronary, endovascular, or structural heart disease and meet all three of the following criteria:

• Addresses an unmet clinical need
• Has preliminary patent application filed
• Includes preclinical or early human clinical data

Guidelines: Describe clinical indication for innovative device or technology. Character limit 2,450, including spaces. Submit 15-20 PowerPoint slides covering aspects of the technology.

Notification: Accepted presenters will be notified in mid-August.

Late-Breaking Clinical Science is typically:

• First-time presentations of first-in-human experiences with novel devices or drugs.
• Primary or important secondary endpoint results of prospective randomized clinical trials.
• Large-scale, impactful single-/multicenter registries.

If your submission is accepted, you will present it at TCT 2023. In addition, a few presentations will be chosen for the press conferences scheduled on the same day.

Embargo: The content of accepted late-breaking science is strictly embargoed until time of presentation.

Non-Qualifying Submissions: Please note that the following rarely qualify as late-breaking clinical trial submissions and instead, should be submitted as abstracts or to call for innovation: preclinical studies, early first-in-human device studies, and meta-analyses.

Guidelines: Total character limit is 3,250, including spaces (primary endpoints: 550-character limit; secondary endpoints: 550-character limit; funding sources: 500 character limit). Upload .png or .jpg files only.

Notification: Accepted presenters will be notified mid-September.